Abstract
AIM: Spleen deficiency (SD)-induced perimenopausal dysfunctional uterine bleeding (PDUB) is a common gynecological disease with various clinical treatment options. The objective of this work was to investigate the clinical effect of female progesterone sequential therapy (FPST) on SD-induced PDUB and follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2).
MRTHOD:140 cases of SD-induced PDUB patients were enrolled and randomly rolled into an observation (Obs) group and a control (Ctrl) group, with 70 cases in each. The patients in the Ctrl group were given pure curettage treatment, and those in the Obs group were supplemented with FPST based on the intervention in the Ctrl group.
Result: The therapeutic effects of patients in different groups were compared. The cure rate (CR) and total effective rate (TER) in the Obs group were 84.26% and 97.14%, respectively, which were much higher to those in the Ctrl group (44.29% and 74.29%), showing great differences (P< 0.05). The incidence of adverse reactions in the Obs group and Ctrl group were 4.29% (3/70) and 2.86% (2/70), respectively, exhibiting no great difference (P> 0.05). Additionally, after 3 months of follow-up, the recurrence rate was 1.43% (1/70) in the Obs group, which was much higher to 44.29% (31/70) in the Ctrl group, presenting a remarkable difference with P< 0.05.
Conclusion: In the process of implementing curettage treatment for PDUB, FPST can effectively improve the clinical treatment effect and reduce recurrence rate.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.